Table 1 Patients characteristics
Characteristics | All | Survived throughout follow-up | Died during follow-up | p-value |
|---|---|---|---|---|
n = 642 | n = 607 | n = 35 | ||
Age (years), mean ± SD | 57.6 ± 9.5 | 57.4 ± 9.4 | 62.3 ± 9.2 | 0.004 |
Gender, n (%) | Â | Â | Â | 0.382 |
 Men | 493 (76.8) | 464 (76.4) | 29 (82.9) |  |
 Women | 149 (23.2) | 143 (23.6) | 6 (17.1) |  |
Body mass index, mean ± SD | 29.8 ± 4.7 | 29.9 ± 4.7 | 29.0 ± 5.2 | 0.355 |
Diagnosis, n (%) | Â | Â | Â | 0.010 |
 Angina pectoris | 159 (24.8) | 149 (24.6) | 10 (28.6) |  |
 Acute myocardial infarction | 405 (63.1) | 381 (62.8) | 24 (68.6) |  |
 Previous myocardial infarction | 78 (12.1) | 77 (12.7) | 1 (2.9) |  |
Angina pectoris class, n (%) | Â | Â | Â | 0.063 |
 I | 143 (22.3) | 138 (22.8) | 5 (14.3) |  |
 II | 214 (33.3) | 196 (32.3) | 18 (51.4) |  |
 III | 18 (2.8) | 16 (2.6) | 2 (5.7) |  |
NYHA, n (%) | Â | Â | Â | <0.001 |
 I | 52 (8.1) | 52 (8.6) | - |  |
 II | 468 (72.9) | 451 (74.2) | 17 (48.6) |  |
 III | 122 (19.0) | 104 (17.2) | 18 (51.4) |  |
Hypertension, n (%) | Â | Â | Â | 0.001 |
 Grade 1 (mild) | 39 (6.1) | 37 (6.1) | 2 (5.7) |  |
 Grade 2 (moderate) | 354 (55.2) | 345 (56.8) | 9 (25.7) |  |
 Grade 3 (severe) | 109 (17.0) | 96 (15.8) | 13 (37.1) |  |
Left ventricular ejection fraction %, mean ± SD | 50.2 ± 9.0 | 50.5 ± 8.9 | 43.4 ± 8.2 | 0.001 |
Diabetes mellitus, n (%) | 74 (11.5) | 67 (11.1) | 7 (20.0) | 0.107 |
Nitrate, n (%) | 255 (39.7) | 233 (38.4) | 22 (62.9) | 0.004 |
Beta-blockers, n (%) | 557 (86.8) | 529 (87.3) | 28 (80.0) | 0.214 |
Angiotensin-converting enzyme inhibitors, n (%) | 527 (82.1) | 496 (81.8) | 31 (88.6) | 0.312 |
Diuretic, n (%) | 101 (15.7) | 92 (15.2) | 9 (25.7) | 0.096 |
N-terminal pro-B-Type natriuretic peptide (ng/L), median (interquartile ranges) | 328.3 (120.8–770.5) | 303.7 (115.7–709.7) | 570.0 (305.5–299.0) | 0.001 |
hs-C-reactive protein (mg/dL), median (interquartile ranges) | 0.26 (0.12–0.58) | 0.26 (0.12–0.57) | 0.47 (0.13–0.88) | 0.077 |
Interleukin-6 (pg/ml), median (interquartile ranges) | 3.1 (1.7–5.5) | 3.1 (1.7–5.5) | 3.7 (2.1–8.0) | 0.209 |
Reverse Triiodothyronine (ng/ml), median (interquartile ranges) | 0.27 (0.22–0.37) | 0.27 (0.22–0.36) | 0.30 (0.20–0.43) | 0.375 |
Free Triiodothyronine (pg/ml), median (interquartile ranges) | 2.80 (2.55–3.06) | 2.80 (2.56–3.06) | 2.72 (2.24–3.00) | 0.036 |
Thyroid-stimulating hormone (μIU/ml), median (interquartile ranges) | 1.8 (1.2–2.6) | 1.8 (1.2–2.8) | 1.7 (1.4–2.5) | 0.875 |
Free Thyroxine (pg/ml), mean ± SD | 13.0 ± 2.5 | 12.9 ± 2.4 | 14.6 ± 3.9 | <0.001 |
Total Triiodothyronine (ng/dl), mean ± SD | 106.7 ± 19.0 | 106.8 ± 19.0 | 104.3 ± 18.3 | 0.519 |
Total Thyroxine (μg/dl), mean ± SD | 7.1 ± 1.5 | 7.8 ± 1.5 | 8.4 ± 1.4 | 0.042 |
Follow-up (months), mean ± SD | 52.0 ± 29.2 | 52.5 ± 29.1 | 43.7 ± 30.6 | 0.029 |